Respiratory Diseases Drugs MGR 2017
July 2017
125
About the Report
About the Report
Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, Chronic obstructive pulmonary disease, chronic and acute bronchitis, Emphysema and cystic fibrosis. Some of the major drugs in the market include Advair /Seretide, Avastin, Singulair, montelukast, prednisone, and azithromycin.
The global respiratory diseases drugs market was estimated to be around $51 billion as of 2016. The respiratory diseases drugs market market made up around 5% of the overall pharmaceuticals market in 2016. The respiratory diseases drugs market was the eleventh market in the global pharmaceutical market in 2016.
Collaborations
Top competitors in the respiratory diseases drugs market are strategically partnering and collaborating with other companies to broaden their product portfolio is a major trend in this market. For instance, in March 2017, AstraZeneca announced collaboration with Circassia Pharmaceuticals plc, (a UK based respiratory biopharmaceutical company) for the development and commercialisation of Tudorza and Duaklir in the US. Tudorza and Duaklir are used in the treatment of chronic obstructive pulmonary disease (COPD).
The Respiratory Diseases Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global respiratory diseases drugs sector.
Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the respiratory diseases drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory diseases drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The respiratory diseases drugs market section of the report gives context. It compares the respiratory diseases drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Respiratory Diseases Drugs Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Anti-Asthma And COPD Products Market, Cough And Cold Preparations
Companies Mentioned: GlaxosmithKline, Novartis AG, Pfizer Inc., Boehringer Ingelheim, and AstraZeneca PLC
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Respiratory Diseases Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Products
Products
Anti-Asthma And COPD Products Market, Cough And Cold Preparations
Companies
GlaxosmithKline, Novartis AG, Pfizer Inc., Boehringer Ingelheim, and AstraZeneca PLC
Table of Contents
Table of Contents
1. Respiratory Diseases Drugs Market Characteristics;
2. Respiratory Diseases Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Respiratory Diseases Drugs Market Customer Information;
5. Respiratory Diseases Drugs Market Segmentation;
5.1. Global Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 5.2. Global Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Respiratory Diseases Drugs Market Trends And Strategies;
6. Respiratory Diseases Drugs Market Regional And Country Analysis;
6.1. Global Respiratory Diseases Drugs Market, 2016, By Region; 6.2. Global Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Respiratory Diseases Drugs Market, 2016, By Country; 6.4. Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Respiratory Diseases Drugs Market Comparison With Macro Economic Factors;
7.1. Respiratory Diseases Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Respiratory Diseases Drugs Expenditure, Global;
8. Respiratory Diseases Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Respiratory Diseases Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Respiratory Diseases Drugs Expenditure, By Country;
9. Respiratory Diseases Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Respiratory Diseases Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Respiratory Diseases Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Respiratory Diseases Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Respiratory Diseases Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Asthma, 2014, By Country; 9.10. Global Number Of General Practitioners 2016, By Country; 9.11. Global Respiratory Diseases Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Respiratory Diseases Drugs Market;
10.1.1. Asia-Pacific Respiratory Diseases Drugs Market Overview; 10.1.2. Asia-Pacific Respiratory Diseases Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Respiratory Diseases Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 10.2. Asia-Pacific Respiratory Diseases Drugs Market: Country Analysis; 10.3. China Respiratory Diseases Drugs Market; 10.3.1. China Respiratory Diseases Drugs Market Overview; 10.3.2. China Respiratory Diseases Drugs Historic Market, 2012-2016; 10.3.3. China Respiratory Diseases Drugs Forecast Market, 2016-2020; 10.3.4. China Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 10.3.5. China Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 10.4. India Respiratory Diseases Drugs Market; 10.4.1. India Respiratory Diseases Drugs Market Overview; 10.4.2. India Respiratory Diseases Drugs Historic Market, 2012-2016; 10.4.3. India Respiratory Diseases Drugs Forecast Market, 2016-2020; 10.4.4. India Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 10.4.5. India Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 10.5. Japan Respiratory Diseases Drugs Market; 10.5.1. Japan Respiratory Diseases Drugs Market Overview; 10.5.2. Japan Respiratory Diseases Drugs Historic Market, 2012-2016; 10.5.3. Japan Respiratory Diseases Drugs Forecast Market, 2016-2020; 10.5.4. Japan Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 10.5.5. Japan Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 10.6. Australia Respiratory Diseases Drugs Market; 10.6.1. Australia Respiratory Diseases Drugs Historic Market, 2012-2016; 10.6.2. Australia Respiratory Diseases Drugs Forecast Market, 2016-2020; 10.6.3. Australia Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 10.6.4. Australia Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020;
11. Western Europe Respiratory Diseases Drugs Market;
11.1.1. Western Europe Respiratory Diseases Drugs Market Overview; 11.1.2. Western Europe Respiratory Diseases Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Respiratory Diseases Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 11.2. Western Europe Respiratory Diseases Drugs Market: Country Analysis; 11.3. UK Respiratory Diseases Drugs Market; 11.3.1. UK Respiratory Diseases Drugs Market Overview; 11.3.2. UK Respiratory Diseases Drugs Historic Market, 2012-2016; 11.3.3. UK Respiratory Diseases Drugs Forecast Market, 2016-2020; 11.3.4. UK Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 11.3.5. UK Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 11.4. Germany Respiratory Diseases Drugs Market; 11.4.1. Germany Respiratory Diseases Drugs Historic Market, 2012-2016; 11.4.2. Germany Respiratory Diseases Drugs Forecast Market, 2016-2020; 11.4.3. Germany Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 11.4.4 Germany Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 11.5 France Respiratory Diseases Drugs Market; 11.5.1 France Respiratory Diseases Drugs Historic Market, 2012-2016; 11.5.2 France Respiratory Diseases Drugs Forecast Market, 2016-2020; 11.5.3 France Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 11.5.4 France Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 11.6. Italy Respiratory Diseases Drugs Market; 11.6.1. Italy Respiratory Diseases Drugs Historic Market, 2012-2016; 11.6.2. Italy Respiratory Diseases Drugs Forecast Market, 2016-2020; 11.6.3. Italy Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 11.6.4. Italy Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020; 11.7. Spain Respiratory Diseases Drugs Market; 11.7.1. Spain Respiratory Diseases Drugs Historic Market, 2012-2016; 11.7.2. Spain Respiratory Diseases Drugs Forecast Market, 2016-2020; 11.7.3. Spain Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 11.7.4. Spain Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020;
12. Eastern Europe Respiratory Diseases Drugs Market;
12.1.1. Eastern Europe Respiratory Diseases Drugs Market Overview; 12.1.2. Eastern Europe Respiratory Diseases Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Respiratory Diseases Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 12.2. Eastern Europe Respiratory Diseases Drugs Market: Country Analysis; 12.3. Russia Respiratory Diseases Drugs Market; 12.3.1. Russia Respiratory Diseases Drugs Historic Market, 2012-2016; 12.3.2. Russia Respiratory Diseases Drugs Forecast Market, 2016-2020; 12.3.3. Russia Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 12.3.4. Russia Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020;
13. North America Respiratory Diseases Drugs Market;
13.1.1. North America Respiratory Diseases Drugs Market Overview; 13.1.2. North America Respiratory Diseases Drugs Historic Market, 2012-2016; 13.1.3. North America Respiratory Diseases Drugs Forecast Market, 2016-2020; 13.1.4. North America Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 13.2. North America Respiratory Diseases Drugs Market: Country Analysis; 13.3. USA Respiratory Diseases Drugs Market; 13.3.1. USA Respiratory Diseases Drugs Historic Market, 2012-2016; 13.3.2. USA Respiratory Diseases Drugs Forecast Market, 2016-2020; 13.3.3 USA Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 13.3.4. USA Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020;
14. South America Respiratory Diseases Drugs Market;
14.1.1. South America Respiratory Diseases Drugs Market Overview; 14.1.2. South America Respiratory Diseases Drugs Historic Market, 2012-2016; 14.1.3. South America Respiratory Diseases Drugs Forecast Market, 2016-2020; 14.1.4. South America Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 14.2. South America Respiratory Diseases Drugs Market: Country Analysis; 14.3. Brazil Respiratory Diseases Drugs Market; 14.3.1. Brazil Respiratory Diseases Drugs Historic Market, 2012-2016; 14.3.2. Brazil Respiratory Diseases Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations; 14.3.4. Brazil Respiratory Diseases Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020;
15. Middle East Respiratory Diseases Drugs Market;
15.1.1. Middle East Respiratory Diseases Drugs Market Overview; 15.1.2. Middle East Respiratory Diseases Drugs Historic Market, 2012-2016; 15.1.3. Middle East Respiratory Diseases Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations;
16. Africa Respiratory Diseases Drugs Market;
16.1.1. Africa Respiratory Diseases Drugs Market Overview; 16.1.2. Africa Respiratory Diseases Drugs Historic Market, 2012-2016; 16.1.2. Africa Respiratory Diseases Drugs Historic Market, 2012-2016; 16.1.3. Africa Respiratory Diseases Drugs Forecast Market, 2016-2020; 16.1.4. Africa Respiratory Diseases Drugs Market, 2016, By Segment; Anti-Asthmatics And COPD Drugs Market; Cough And Cold Preparations;
17. Respiratory Diseases Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. GlaxoSmithKline; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Novartis Ag; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Pfizer Inc.; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Boehringer Ingelheim; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Astrazeneca Plc; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Respiratory Diseases Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
List of Figure
Table 1: Global Respiratory Diseases Drugs Historic Market Growth
Table 2: Global Respiratory Diseases Drugs Forecast Market Growth
Table 3: Respiratory Diseases Drugs Market Segmentation
Table 4: Global Respiratory Diseases Drugs Market, 2016, By Segment
Table 5: Global Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Segment
Table 6: Global Respiratory Diseases Drugs Market, 2016, By Region
Table 7: Global Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 8: Respiratory Diseases Drugs Market, 2016, By Country
Table 9: Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 10: Global Pharmaceutical Market Segments, 2016, By Region
Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Table 12: Global Pharmaceutical Market Segments, 2016, By Country
Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Table 14: Respiratory Diseases Drugs Market Size, Percentage Of GDP, Global
Table 15: Per Capita Average Respiratory Diseases Drugs Expenditure, Global
Table 16: Respiratory Diseases Drugs Market Comparison With Macro Economic Factors Across Countries
Table 17: Respiratory Diseases Drugs Market Size, Percentage Of GDP, By Country
Table 18: Per Capita Average Respiratory Diseases Drugs Expenditure, By Country
Table 19: Global Number Of Pharmacists, 2016, By Country
Table 20: Global Respiratory Diseases Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 21: Global Number Of Pharma Enterprises, 2016, By Country
Table 22: Global Respiratory Diseases Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 23: Global Average Spending On R&D/Product Development, 2016, By Country
Table 24: Global Respiratory Diseases Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 26: Global Respiratory Diseases Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 27: Prevalent Cases Of Asthma, 2014, By Country
Table 28: Global Number Of General Practitioners 2016, By Country
Table 29: Global Respiratory Diseases Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
Table 30: Asia-Pacific Respiratory Diseases Drugs Historic Market, 2012-2016
Table 31: Asia-Pacific Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 32: Asia-Pacific Respiratory Diseases Drugs Market, 2016, By Segment
Table 33: China Respiratory Diseases Drugs Historic Market, 2012-2016
Table 34: China Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 35: China Respiratory Diseases Drugs Market, 2016, By Segment
Table 36: China Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 37: China Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 38: India Respiratory Diseases Drugs Historic Market, 2012-2016
Table 39: India Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 40: India Respiratory Diseases Drugs Market, 2016, By Segment
Table 41: India Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 42: India Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 43: Japan Respiratory Diseases Drugs Historic Market, 2012-2016
Table 44: Japan Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 45: Japan Respiratory Diseases Drugs Market, 2016, By Segment
Table 46: Japan Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 47: Japan Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 48: Australia Respiratory Diseases Drugs Historic Market, 2012-2016
Table 49: Australia Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 50: Australia Respiratory Diseases Drugs Market, 2016, By Segment
Table 51: Australia Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 52: Australia Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 53: Western Europe Respiratory Diseases Drugs Historic Market, 2012-2016
Table 54: Western Europe Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 55: Western Europe Respiratory Diseases Drugs Market, 2016, By Segment
Table 56: UK Respiratory Diseases Drugs Historic Market, 2012-2016
Table 57: UK Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 58: UK Respiratory Diseases Drugs Market, 2016, By Segment
Table 59: UK Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 60: UK Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 61: Germany Respiratory Diseases Drugs Historic Market, 2012-2016
Table 62: Germany Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 63: Germany Respiratory Diseases Drugs Market, 2016, By Segment
Table 64: Germany Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 65: Germany Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 66: France Respiratory Diseases Drugs Historic Market, 2012-2016
Table 67: France Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 68: France Respiratory Diseases Drugs Market, 2016, By Segment
Table 69: France Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 70: France Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 71: Italy Respiratory Diseases Drugs Historic Market, 2012-2016
Table 72: Italy Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 73: Italy Respiratory Diseases Drugs Market, 2016, By Segment
Table 74: Italy Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 75: Italy Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 76: Spain Respiratory Diseases Drugs Historic Market, 2012-2016
Table 77: Spain Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 78: Spain Respiratory Diseases Drugs Market, 2016, By Segment
Table 79: Spain Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 80: Spain Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 81: Eastern Europe Respiratory Diseases Drugs Historic Market, 2012-2016
Table 82: Eastern Europe Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 83: Eastern Europe Respiratory Diseases Drugs Market, 2016, By Segment
Table 84: Russia Respiratory Diseases Drugs Historic Market, 2012-2016
Table 85: Russia Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 86: Russia Respiratory Diseases Drugs Market, 2016, By Segment
Table 87: Russia Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 88: Russia Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 89: North America Respiratory Diseases Drugs Historic Market, 2012-2016
Table 90: North America Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 91: North America Respiratory Diseases Drugs Market, 2016, By Segment
Table 92: USA Respiratory Diseases Drugs Historic Market, 2012-2016
Table 93: USA Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 94: USA Respiratory Diseases Drugs Market, 2016, By Segment
Table 95: USA Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 96: USA Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 97: South America Respiratory Diseases Drugs Historic Market, 2012-2016
Table 98: South America Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 99: South America Respiratory Diseases Drugs Market, 2016, By Segment
Table 100: Brazil Respiratory Diseases Drugs Historic Market, 2012-2016
Table 101: Brazil Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 102: Brazil Respiratory Diseases Drugs Market, 2016, By Segment
Table 103: Brazil Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Table 104: Brazil Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Table 105: Middle East Respiratory Diseases Drugs Historic Market, 2012-2016
Table 106: Middle East Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 107: Middle East Respiratory Diseases Drugs Market, 2016, By Segment
Table 108: Africa Respiratory Diseases Drugs Historic Market, 2012-2016
Table 109: Africa Respiratory Diseases Drugs Forecast Market, 2016-2020
Table 110: Africa Respiratory Diseases Drugs Market, 2016, By Segment
Table 111: Glaxosmithkline Financial Performance
Table 112: Novartis Ag Financial Performance
Table 113: Pfizer Inc. Financial Performance
Table 114: Boehringer Ingelheim Financial Performance
Table 115: Astrazeneca Plc Financial Performance
Table 116: Pharmaceutical Drugs Market Historic Growth
Table 117: Pharmaceutical Drugs Market Forecast Growth
Table 118: Global Pharmaceutical Drugs Market, 2016, By Region
Table 119: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 120: Pharmaceutical Drugs Market, 2016, By Country
Table 121: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 122: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Table 124: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Table 125: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Table 126: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Table 127: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Table 128: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Table 129: Pharmaceuticals Industry Financial Margins
List of Table
Figure 1: Global Respiratory Diseases Drugs Historic Market Growth
Figure 2: Global Respiratory Diseases Drugs Forecast Market Growth
Figure 3: Respiratory Diseases Drugs Market Segmentation
Figure 4: Global Respiratory Diseases Drugs Market, 2016, By Segment
Figure 5: Global Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Segment
Figure 6: Global Respiratory Diseases Drugs Market, 2016, By Region
Figure 7: Global Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 8: Respiratory Diseases Drugs Market, 2016, By Country
Figure 9: Respiratory Diseases Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 10: Global Pharmaceutical Market Segments, 2016, By Region
Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Figure 12: Global Pharmaceutical Market Segments, 2016, By Country
Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Figure 14: Respiratory Diseases Drugs Market Size, Percentage Of GDP, Global
Figure 15: Per Capita Average Respiratory Diseases Drugs Expenditure, Global
Figure 16: Respiratory Diseases Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 17: Respiratory Diseases Drugs Market Size, Percentage Of GDP, By Country
Figure 18: Per Capita Average Respiratory Diseases Drugs Expenditure, By Country
Figure 19: Global Number Of Pharmacists, 2016, By Country
Figure 20: Global Respiratory Diseases Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 21: Global Number Of Pharma Enterprises, 2016, By Country
Figure 22: Global Respiratory Diseases Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 24: Global Respiratory Diseases Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 26: Global Respiratory Diseases Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 27: Prevalent Cases Of Asthma, 2014, By Country
Figure 28: Global Number Of General Practitioners 2016, By Country
Figure 29: Global Respiratory Diseases Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
Figure 30: Asia-Pacific Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 31: Asia-Pacific Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 32: Asia-Pacific Respiratory Diseases Drugs Market, 2016, By Segment
Figure 33: China Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 34: China Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 35: China Respiratory Diseases Drugs Market, 2016, By Segment
Figure 36: China Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 37: China Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 38: India Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 39: India Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 40: India Respiratory Diseases Drugs Market, 2016, By Segment
Figure 41: India Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 42: India Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 43: Japan Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 44: Japan Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 45: Japan Respiratory Diseases Drugs Market, 2016, By Segment
Figure 46: Japan Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 47: Japan Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 48: Australia Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 49: Australia Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 50: Australia Respiratory Diseases Drugs Market, 2016, By Segment
Figure 51: Australia Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 52: Australia Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 53: Western Europe Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 54: Western Europe Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 55: Western Europe Respiratory Diseases Drugs Market, 2016, By Segment
Figure 56: UK Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 57: UK Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 58: UK Respiratory Diseases Drugs Market, 2016, By Segment
Figure 59: UK Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 60: UK Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 61: Germany Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 62: Germany Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 63: Germany Respiratory Diseases Drugs Market, 2016, By Segment
Figure 64: Germany Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 65: Germany Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 66: France Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 67: France Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 68: France Respiratory Diseases Drugs Market, 2016, By Segment
Figure 69: France Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 70: France Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 71: Italy Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 72: Italy Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 73: Italy Respiratory Diseases Drugs Market, 2016, By Segment
Figure 74: Italy Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 75: Italy Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 76: Spain Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 77: Spain Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 78: Spain Respiratory Diseases Drugs Market, 2016, By Segment
Figure 79: Spain Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 80: Spain Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 81: Eastern Europe Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 82: Eastern Europe Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 83: Eastern Europe Respiratory Diseases Drugs Market, 2016, By Segment
Figure 84: Russia Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 85: Russia Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 86: Russia Respiratory Diseases Drugs Market, 2016, By Segment
Figure 87: Russia Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 88: Russia Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 89: North America Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 90: North America Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 91: North America Respiratory Diseases Drugs Market, 2016, By Segment
Figure 92: USA Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 93: USA Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 94: USA Respiratory Diseases Drugs Market, 2016, By Segment
Figure 95: USA Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 96: USA Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 97: South America Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 98: South America Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 99: South America Respiratory Diseases Drugs Market, 2016, By Segment
Figure 100: Brazil Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 101: Brazil Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 102: Brazil Respiratory Diseases Drugs Market, 2016, By Segment
Figure 103: Brazil Respiratory Diseases Drugs Percentage Of GDP, 2012-2020
Figure 104: Brazil Per Capita Average Respiratory Diseases Drugs Expenditure, 2012-2020
Figure 105: Middle East Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 106: Middle East Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 107: Middle East Respiratory Diseases Drugs Market, 2016, By Segment
Figure 108: Africa Respiratory Diseases Drugs Historic Market, 2012-2016
Figure 109: Africa Respiratory Diseases Drugs Forecast Market, 2016-2020
Figure 110: Africa Respiratory Diseases Drugs Market, 2016, By Segment
Figure 111: Glaxosmithkline Financial Performance
Figure 112: Novartis Ag Financial Performance
Figure 113: Pfizer Inc. Financial Performance
Figure 114: Boehringer Ingelheim Financial Performance
Figure 115: Astrazeneca Plc Financial Performance
Figure 116: Pharmaceutical Drugs Market Historic Growth
Figure 117: Pharmaceutical Drugs Market Forecast Growth
Figure 118: Global Pharmaceutical Drugs Market, 2016, By Region
Figure 119: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 120: Pharmaceutical Drugs Market, 2016, By Country
Figure 121: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 122: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Figure 124: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Figure 125: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Figure 126: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 127: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Figure 128: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Figure 129: Pharmaceuticals Industry Financial Margins
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.